Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q00005
UPID:
2ABB_HUMAN
Alternative names:
PP2A subunit B isoform B55-beta; PP2A subunit B isoform PR55-beta; PP2A subunit B isoform R2-beta; PP2A subunit B isoform beta
Alternative UPACC:
Q00005; A6NEJ2; A8K102; B3KPD0; B7Z2F2; B7Z304; D3DQF7; D3DQF8; G3V149
Background:
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B beta isoform, known by alternative names such as PP2A subunit B isoform B55-beta, plays a crucial role in cellular processes. It modulates substrate selectivity, catalytic activity, and directs the catalytic enzyme to specific subcellular compartments. Its involvement in promoting proapoptotic activity and regulating neuronal survival through mitochondrial dynamics highlights its multifaceted biological functions.
Therapeutic significance:
Spinocerebellar ataxia 12, a disorder characterized by progressive incoordination and degeneration of the cerebellum, is linked to variants affecting this protein. Understanding the role of Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B beta isoform could open doors to potential therapeutic strategies for this and related cerebellar disorders.